back to Directory

Septerna (acquired by Vertex Pharmaceuticals)

Septerna logo

Founded
2022
Publications
4

Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches, we have built an industrialized platform to precisely control and modulate GPCR biology and pharmacology to discover and develop new high-impact medicines. With our Native Complex™ platform, we are opening a new frontier in GPCR small molecule discovery technologies to expand the druggable GPCR landscape.


Posts Mentioning This Company

2022 in Retrospect: 10 Breakthrough Technologies in Drug Discovery

  
Reflecting on 2022, let’s review several breakthrough technologies that are shaping the future of biology research and drug discovery. I have prepared this list based on a review of recent articles published on BiopharmaTrend -- by myself and by numerous guest authors.